Boule Diagnostics AB (BOUL)

Currency in SEK
6.40
+0.06(+0.95%)
Closed·
BOUL Scorecard
Full Analysis
Net income is expected to grow this year
BOUL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.326.50
52 wk Range
6.1410.60
Key Statistics
Prev. Close
6.34
Open
6.32
Day's Range
6.32-6.5
52 wk Range
6.14-10.6
Volume
31.72K
Average Volume (3m)
80.93K
1-Year Change
-27.46%
Book Value / Share
4.16
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BOUL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.50
Upside
+17.19%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Boule Diagnostics AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Boule Diagnostics AB Company Profile

Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics companies. Boule Diagnostics AB (publ) was founded in 1956 and is headquartered in Spånga, Sweden.

Employees
200
Market
Sweden

Boule Diagnostics AB Earnings Call Summary for Q2/2025

  • Q2 2025 revenue fell 5.6% to SEK 129M, gross margin dropped to 38.7%, stock plummeted 29.71% to SEK 7.24
  • Doubled sales of M51 five-part instrument units, reduced operating expenses by 47%, achieved positive operating cash flow
  • Faced challenges in US and Latin America, saw growth in Southeast Asia and Europe through veterinary sales
  • Management expects stabilizing instrument pricing and continued sales funnel development in H2 2025
  • Company maintains optimism despite challenges, focuses on cost optimization and strategic initiatives in OEM and blood controls
Last Updated: 18/07/2025, 09:26
Read Full Transcript

Compare BOUL to Peers and Sector

Metrics to compare
BOUL
Peers
Sector
Relationship
P/E Ratio
−0.8x−10.6x−0.5x
PEG Ratio
0.00−0.100.00
Price/Book
1.5x2.9x2.6x
Price / LTM Sales
0.5x817.8x3.3x
Upside (Analyst Target)
16.5%0.0%43.5%
Fair Value Upside
Unlock3.3%6.9%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.50
(+17.19% Upside)

Earnings

Latest Release
Jul 18, 2025
EPS / Forecast
-0.03 / 0.22
Revenue / Forecast
129.30M / 131.00M
EPS Revisions
Last 90 days

BOUL Income Statement

FAQ

What Stock Exchange Does Boule Diagnostics Trade On?

Boule Diagnostics is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Boule Diagnostics?

The stock symbol for Boule Diagnostics is "BOUL."

What Is the Boule Diagnostics Market Cap?

As of today, Boule Diagnostics market cap is 248.53M.

What Is Boule Diagnostics's Earnings Per Share (TTM)?

The Boule Diagnostics EPS (TTM) is -8.21.

When Is the Next Boule Diagnostics Earnings Date?

Boule Diagnostics will release its next earnings report on 23 Oct 2025.

From a Technical Analysis Perspective, Is BOUL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Boule Diagnostics Stock Split?

Boule Diagnostics has split 1 times.

How Many Employees Does Boule Diagnostics Have?

Boule Diagnostics has 200 employees.

What is the current trading status of Boule Diagnostics (BOUL)?

As of 07 Aug 2025, Boule Diagnostics (BOUL) is trading at a price of 6.40, with a previous close of 6.34. The stock has fluctuated within a day range of 6.32 to 6.50, while its 52-week range spans from 6.14 to 10.60.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.